Using whole brain imaging for development of obesity drugs
Webinar date: May 2, 2023 Host: Jacob Hecksher-Sørensen
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes
European Journal of Pharmacology 815:181–189, 2017
A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
ACS Chemical Biology 12(8):2107–2116, 2017
The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
Peptides 69:47–55, 2015
Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis
Diabetes 64(3):1046–56, 2015
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
American Journal of Physiolology - Endocrinology and Metabolism 303:E253-E264, 2012
Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight
Diabetes Obesity & Metabolism 14(6):531–538, 2012